Broadens CREATE's delivery toolkit with access to Monash's novel LNP chemistries and next-generation targeting technologies.
Enables rapid evaluation of diverse binder formats and cell-targeting strategies, accelerating development across multiple immune cell types and therapeutic programs.
CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced a strategic research collaboration with Australia's Monash University and its world-leading Monash Institute of Pharmaceutical Sciences (MIPS). The partnership broadens CREATE's portfolio by accessing Monash's advanced lipid nanoparticle (LNP) technology including proprietary binders and chemistry, strengthening its leadership in developing best-in-class targeted in vivo therapies. Targeted delivery remains one of the primary challenges in realising the full therapeutic potential of in vivo cell therapies, requiring increasingly precise control over which immune cells receive therapeutic payloads.
Together, CREATE and MIPS will jointly advance targeted Chimeric Antigen Receptor (CAR) therapy, with the goal of enabling precise, cell-type-specific in vivo delivery of CAR payloads utilising the targeted LNP technology. Under the agreement, CREATE receives a worldwide exclusive license to all intellectual property, arising from the collaboration, together with the right to develop and commercialise CAR products directed to designated CAR targets. In turn, MIPS will receive research funding and downstream milestone and royalty payments.
Daniel Getts, PhD, Founder and Chief Executive Officer of CREATE Medicines said: "Monash brings world-class LNP engineering and paired with our already clinically validated and targeted mRNA platform, we can further apply that precision across an even broader range of targets."
"Together, we will unlock a new generation of programmable medicines that reach more patients than ever before."
"Monash has built deep expertise in targeted LNP delivery, and their binder and chemistry innovations pair powerfully with our in vivo CAR platform," said Robert Hofmeister, PhD, Chief Scientific Officer of CREATE. "Together we're building a richer targeting toolkit with new binder formats and control that gives us even more ways to program the right cells with precision."
Monash Vice-Chancellor and President Professor Sharon Pickering said: "Our new strategic partnership with CREATE Medicines will accelerate the work of Monash's world leading pharmaceutical researchers to design new immunotherapies and speed the translation of their work into new life-changing cancer treatments."
"As a globally ranked top-40 university and the most industry-connected university in Australia, Monash is at the heart of a health and medical innovation ecosystem – extending to a commercial office in Boston, the world's biotech capital – that is leveraging industry, education, research and innovation at scale."
The research at Monash will be led by a distinguished team of scientific experts. Professor Angus Johnston, a leading expert in nanoparticle delivery biology and intracellular trafficking, will serve as Principal Investigator. He will be supported by Professor Colin Pouton, and Dr Moore Chen, who co-authored a seminal 2025 Nature Nanotechnology paper pioneering a new method of delivering mRNA to target cells.
"We're excited to partner with CREATE to advance a shared vision for programmable medicines" said Professor Johnston. "Targeted delivery is one of the central challenges in realising the promise of in vivo cell therapies and pairing our LNP technology with CREATE's platform is a powerful step toward solving it."
Assets Available
About CREATE Medicines
CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly engineers T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. CREATE is advancing a pipeline of in vivo CAR therapies across autoimmune diseases and cancer.
